Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Q32 Bio Inc. (Nasdaq: QTTB ), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten public offering of 6,027,399 shares of its common stock at a public offering price of $18.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 4,931,506 shares of its common stock at a public offering price of $18.2499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. In addition, Q32 Bio has granted the underwriters a 30-day option to purchase up to an additional 1,643,835 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Q32 Bio from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Q32 Bio, are expected to be approximately $200 million, assuming no exercise of the underwriters' option to purchase additional shares and excluding any exercise of the pre-funded warrants. The offering is expected to close on or about July 16, 2026, subject to the satisfaction of customary closing conditions. All shares and pre-funded warrants in the offering are being sold by Q32 Bio. Morgan Stanley, Jefferies and Cantor are acting as joint book-running managers for the offering. Oppenheimer & Co. is also acting as a book-running manager for the offering, and H.C. Wainwright & Co. is acting as lead manager for the offering. Q32 Bio intends to use the net proceeds of the offering for working capital purposes, including expenses related to research, clinical development and commercialization efforts including for supporting the advancement of bempikibart into future clinical trials.